<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27470096</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.</ArticleTitle><Pagination><StartPage>30648</StartPage><MedlinePgn>30648</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">30648</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep30648</ELocationID><Abstract><AbstractText>We developed a novel platform to express high levels of recombinant lipoproteins with intrinsic adjuvant properties. Based on this technology, our group developed recombinant lipidated dengue envelope protein domain IIIs as vaccine candidates against dengue virus. This work aims to evaluate the immune responses in mice to the tetravalent formulation. We demonstrate that 4 serotypes of recombinant lipidated dengue envelope protein domain III induced both humoral and cellular immunity against all 4 serotypes of dengue virus on the mixture that formed the tetravalent formulation. Importantly, the immune responses induced by the tetravalent formulation in the absence of the exogenous adjuvant were functional in clearing the 4 serotypes of dengue virus in vivo. We affirm that the tetravalent formulation of recombinant lipidated dengue envelope protein domain III is a potential vaccine candidate against dengue virus and suggest further detailed studies of this formulation in nonhuman primates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Chen-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chien-Hsiung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Yu</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Chun-Hsiang</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jy-Ping</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hsueh-Hung</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Chih-Hsiang</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058501" MajorTopicYN="N">Enzyme-Linked Immunospot Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>HWC, CHL, SJL, and PC are named on patents relating to the lipidated vaccine against dengue virus infection.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27470096</ArticleId><ArticleId IdType="pmc">PMC4965760</ArticleId><ArticleId IdType="doi">10.1038/srep30648</ArticleId><ArticleId IdType="pii">srep30648</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guzman M. G. &amp; Kouri G. Dengue: an update. Lancet Infect Dis 2, 33&#x2013;42 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11892494</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady O. J. et al.. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLos neglected tropical diseases 6, e1760 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413714</ArticleId><ArticleId IdType="pubmed">22880140</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales S., de Wet N., Maindonald J. &amp; Woodward A. Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet 360, 830&#x2013;834 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12243917</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S. et al.. The global distribution and burden of dengue. Nature 496, 504&#x2013;507 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo L., Roque V. G., Brett J., Dizon R. &amp; L&#x2019;Azou M. Epidemiology of dengue disease in the Philippines (2000-2011): a systematic literature review. PLos neglected tropical diseases 8, e3027 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222740</ArticleId><ArticleId IdType="pubmed">25375119</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantes H. G., Farfan-Ale J. A. &amp; Sarti E. Epidemiological trends of dengue disease in Mexico (2000&#x2013;2011): a systematic literature search and analysis. PLos neglected tropical diseases 8, e3158 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222737</ArticleId><ArticleId IdType="pubmed">25375162</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#x2019;Azou M., Taurel A. F., Flamand C. &amp; Quenel P. Recent epidemiological trends of dengue in the French territories of the Americas (2000&#x2013;2012): a systematic literature review. PLos neglected tropical diseases 8, e3235 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222734</ArticleId><ArticleId IdType="pubmed">25375627</ArticleId></ArticleIdList></Reference><Reference><Citation>Limkittikul K., Brett J. &amp; L&#x2019;Azou M. Epidemiological trends of dengue disease in Thailand (2000&#x2013;2011): a systematic literature review. PLoS neglected tropical diseases 8, e3241 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222696</ArticleId><ArticleId IdType="pubmed">25375766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd-Zaki A. H., Brett J., Ismail E. &amp; L&#x2019;Azou M. Epidemiology of dengue disease in Malaysia (2000&#x2013;2012): a systematic literature review. PLos neglected tropical diseases 8, e3159 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4222702</ArticleId><ArticleId IdType="pubmed">25375211</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira M. G., Siqueira J. B. Jr., Ferreira G. L., Bricks L. &amp; Joint G. Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. PLos neglected tropical diseases 7, e2520 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3871634</ArticleId><ArticleId IdType="pubmed">24386496</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar L. A., Rojas D. P., Besada-Lombana S. &amp; Sarti E. Epidemiological trends of dengue disease in Colombia (2000&#x2013;2011): a systematic review. PLos neglected tropical diseases 9, e0003499 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4366106</ArticleId><ArticleId IdType="pubmed">25790245</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M. G. &amp; Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol 27, 1&#x2013;13 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12727523</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller B. A. &amp; Clements D. E. Dengue vaccines: progress and challenges. Current opinion in immunology 23, 391&#x2013;398 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21514129</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding M. R. et al.. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384, 1358&#x2013;1365 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25018116</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar L. et al.. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372, 113&#x2013;123 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25365753</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadinegoro S. R. et al.. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med 373, 1195&#x2013;1206 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y. et al.. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3, 866&#x2013;871 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9256277</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill W. D. &amp; Roehrig J. T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75, 7769&#x2013;7773 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung J.-J. et al.. An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells. J. Virol. 78, 378&#x2013;388 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC303388</ArticleId><ArticleId IdType="pubmed">14671119</ArticleId></ArticleIdList></Reference><Reference><Citation>Thullier P. et al.. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82, 1885&#x2013;1892 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11457994</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig J. T., Bolin R. A. &amp; Kelly R. G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317&#x2013;328 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9657950</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzarte E. et al.. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol 27, 367&#x2013;379 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25795768</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu J. P. et al.. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26, 4655&#x2013;4663 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18640168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L. et al.. The two component adjuvant IC31(R) potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine 29, 4256&#x2013;4263 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21447316</ArticleId></ArticleIdList></Reference><Reference><Citation>Block O. K. et al.. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 28, 8085&#x2013;8094 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20959154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C. Y. et al.. Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses. PLos neglected tropical diseases 6, e1645 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352863</ArticleId><ArticleId IdType="pubmed">22616020</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng C. H. et al.. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11, 288&#x2013;295 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuest R. et al.. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice. Vaccine 33, 1474&#x2013;1482 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25659270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L. et al.. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80, 194&#x2013;199 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18602424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. W. et al.. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol 158, 1523&#x2013;1531 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23456422</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida L. et al.. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24, 3165&#x2013;3171 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons M., Porter K. R., Hayes C. G., Vaughn D. W. &amp; Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80, 9577&#x2013;9585 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1617260</ArticleId><ArticleId IdType="pubmed">16973561</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes I. et al.. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 27, 995&#x2013;1001 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19100804</ArticleId></ArticleIdList></Reference><Reference><Citation>Brightbill H. D. et al.. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285, 732&#x2013;736 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10426995</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. W. et al.. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 27, 1400&#x2013;1409 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19150476</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng C. H. et al.. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol 47, 2015&#x2013;2021 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20478617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C. Y. et al.. A novel single-dose dengue subunit vaccine induces memory immune responses. PLos One 6, e23319 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149651</ArticleId><ArticleId IdType="pubmed">21826249</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C. Y. et al.. Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement. PLoS neglected tropical diseases 7, e2432 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="pubmed">24069487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C. Y. et al.. Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice. Vaccine 34, 1054&#x2013;1061 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26776472</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C. Y. et al.. Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III. Microbes Infect 15, 719&#x2013;728 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23774693</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C. Y. et al.. Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine 32, 1346&#x2013;1353 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24486311</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka A. &amp; Konishi E. A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells. Vaccine 27, 3735&#x2013;3743 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19464557</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B. et al.. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80, 302&#x2013;311 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19190230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanesa-thasan N. et al.. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179&#x2013;3188 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11312014</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan S., Khanna N., Herring B. &amp; Mahalingam S. Dengue vaccine efficacy trial: does interference cause failure? Lancet Infect Dis 13, 191&#x2013;192 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23427882</ArticleId></ArticleIdList></Reference><Reference><Citation>Puschnik A. et al.. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLos neglected tropical diseases 7, e2274 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681624</ArticleId><ArticleId IdType="pubmed">23785536</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau L., Green A. M., Balmaseda A. &amp; Harris E. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity. J Clin Virol 69, 63&#x2013;67 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978614</ArticleId><ArticleId IdType="pubmed">26209381</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch L. E. et al.. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185, 5405&#x2013;5416 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962919</ArticleId><ArticleId IdType="pubmed">20870934</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch L. E. et al.. A protective role for dengue virus-specific CD8+ T cells. J Immunol 182, 4865&#x2013;4873 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674070</ArticleId><ArticleId IdType="pubmed">19342665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zompi S., Santich B. H., Beatty P. R. &amp; Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol 188, 404&#x2013;416 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244532</ArticleId><ArticleId IdType="pubmed">22131327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman A. L., Kurane I. &amp; Ennis F. A. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J Virol 70, 6540&#x2013;6546 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190694</ArticleId><ArticleId IdType="pubmed">8794288</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. W. et al.. The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice. PLos One 10, e0145717 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4695087</ArticleId><ArticleId IdType="pubmed">26714037</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclerc C. et al.. Identification of helper T cell epitopes of dengue virus E-protein. Mol Immunol 30, 613&#x2013;625 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">7683752</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig J. T. et al.. T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology 198, 31&#x2013;38 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7505071</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D. et al.. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci USA 110, E2046&#x2013;E2053 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670335</ArticleId><ArticleId IdType="pubmed">23580623</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D. et al.. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 89, 120&#x2013;128 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301095</ArticleId><ArticleId IdType="pubmed">25320311</ArticleId></ArticleIdList></Reference><Reference><Citation>Imoto J. &amp; Konishi E. Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine. Vaccine 25, 1076&#x2013;1084, (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17084490</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin A. P. et al.. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376, 429&#x2013;435 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546568</ArticleId><ArticleId IdType="pubmed">18452966</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>